Many scientists previously thought that a diabetes drug named Actos increases bladder cancer risk. However, quashing the previous findings, a new study suggests that use of Actos is much safer than thought previously and there isn’t any risk associated with the drug.
According to the study appeared in the journal American Medical Association, there isn’t solid evidence that interlinks Actos with bladder cancer risk instead the study found an interlink between use of Actos and increased risk of pancreatic cancer. However, study authors said that the findings are still on early stages and a deeper study needs to be done for better understanding.
For the study, a team led by Assiamira Ferrara from Northern California analysed nearly 2,00,000 diabetes patients for a long period of time and found no statistically significant association between taking Actos and increased risk of bladder cancer. However, researcher Igor Astsaturov found an interlink between Actos and pancreatic cancer risk. He explained that one of the key elements in pancreatic cancer is inflammation and chronic inflammation is common in diabetic people.
Astsaturov further added that people in higher stages of diabetes are more likely to face chronic inflammation, also they are more likely to be prescribed Actos. This might be the reason that researchers found statistical link between Actos and increased pancreatic cancer risk, he said.
Moreover, Actos is pioglitazone and should be taken with care as it has several other side effects including stomach ache, painful urination, breathing problem, chest pain, nausea, itching, loss of appetite, blood in urine, etc. After seeking any of these symptoms visit nearest doctor as soon as possible.